2013-03-20 14:29:16 - New Pharmaceuticals market report from Global Markets Direct: "Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H2 2012"
Global Markets Direct's, 'Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Streptococcus Pneumoniae (Pneumococcus) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae (Pneumococcus) Infections. Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Full Report Details at
- www.fastmr.com/prod/527931_streptococcus_pneumoniae_pneumococcus ..
sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
* A snapshot of the global therapeutic scenario for Streptococcus Pneumoniae (Pneumococcus) Infections.
* A review of the Streptococcus Pneumoniae (Pneumococcus) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Streptococcus Pneumoniae (Pneumococcus) Infections pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to buy
* Identify and understand important and diverse types of therapeutics under development for Streptococcus Pneumoniae (Pneumococcus) Infections.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Streptococcus Pneumoniae (Pneumococcus) Infections pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Partial Table of Contents:
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Global Markets Direct Report Coverage 8
Streptococcus Pneumoniae (Pneumococcus) Infections Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Streptococcus Pneumoniae (Pneumococcus) Infections 10
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics under Development by Companies 12
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics - Products under Development by Companies 20
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics Development 23
GlaxoSmithKline plc 23
Daiichi Sankyo Company, Ltd 24
Merck & Co., Inc. 25
Dainippon Sumitomo Pharma Co., Ltd. 26
ACE BioSciences A/S 27
Intercell AG 28
SIGA Technologies, Inc. 29
Panacea Biotec Limited 30
Eurocine Vaccines AB 31
China National Biotec Group 32
Mucosis B.V. 33
GlycoVaxyn AG 34
Aquapharm Biodiscovery Limited 35
aRigen Pharmaceuticals, Inc. 36
Nabriva Therapeutics AG 37
Sinovac Biotech Ltd. 38
Genocea Biosciences, Inc. 39
NasVax Ltd. 40
Morphochem AG 41
Streptococcus Pneumoniae (Pneumococcus) Infections - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
Pneumococcal Conjugate Vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Sortase Inhibitor - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BC-3781 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Pneumococcus Antibodies - Drug Profile 52
Product Description 52
Mechanism of Action 52
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.